Citation Impact
Citing Papers
Normalization of Real-Time Quantitative Reverse Transcription-PCR Data: A Model-Based Variance Estimation Approach to Identify Genes Suited for Normalization, Applied to Bladder and Colon Cancer Data Sets
2004 Standout
Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
2014 Standout
Chemoprevention of BBN-Induced Bladder Carcinogenesis by the Selective Estrogen Receptor Modulator Tamoxifen
2013
ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
2004 Standout
MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas
1999
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
2016 Standout
Updated concepts and treatment of carcinoma in situ
1998
Nuclear volume and expression of T-antigen, sialosyl-Tn-antigen, and Tn-antigen in carcinoma of the human bladder. Relation to tumor recurrence and progression
1992
Lycopene: Chemistry, Biology, and Implications for Human Health and Disease
2009 Standout
Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250.
1997
UDPgalactose:glycoprotein–N‐acetyl‐d ‐galactosamine 3‐β‐d ‐galactosyltransferase activity synthesizing O‐glycan core 1 is controlled by the amino acid sequence and glycosylation of glycopeptide substrates
1994 StandoutNobel
The effect of age and gender on bladder cancer: a critical review of the literature
2009
Identifying distinct classes of bladder carcinoma using microarrays
2002
Role of androgen receptor and associated lysine‐demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer
2011
De novo domestication of wild tomato using genome editing
2018 Standout
Genome Mapping and Molecular Breeding of Tomato
2007 Standout
Carotenoids and human health
2007 Standout
Delivery technologies for cancer immunotherapy
2019 Standout
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
2013 Standout
Measuring reactive species and oxidative damagein vivoand in cell culture: how should you do it and what do the results mean?
2004 Standout
-Catenin mutation in rat colon tumors initiated by 1,2-dimethylhydrazine and 2-amino-3-methylimidazo[4,5-f]quinoline, and the effect of post-initiation treatment with chlorophyllin and indole-3-carbinol
2001 Standout
Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer
2002 Standout
Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials
2006 Standout
EAU Guidelines on the Diagnosis and Treatment of Urothelial Carcinoma in Situ
2005
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
2016 Standout
Tomatoes, Tomato-Based Products, Lycopene, and Cancer: Review of the Epidemiologic Literature
1999 Standout
Chemoprevention of Cancer
2004
EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction
2013 Standout
Recurrence and Progression of Disease in Non–Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy
2009 Standout
Dysregulated pH: a perfect storm for cancer progression
2011 Standout
Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
2013
Epidemiology and Risk Factors of Urothelial Bladder Cancer
2012 Standout
Drug discovery from medicinal plants
2005 Standout
Impact of gender on bladder cancer incidence, staging, and prognosis
2011
Role of Free Radicals in the Neurodegenerative Diseases
2001 Standout
The impact of female gender on bladder cancer-specific death risk after radical cystectomy: a meta-analysis of 27,912 patients
2015
Points of control in inflammation
2002 StandoutNature
High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder
2005
Intravesical Therapy of Bladder Cancer: An lmmunotherapy Success Story
1996
Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
2017 Standout
EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
2008 Standout
Regulatory networks defining EMT during cancer initiation and progression
2013 Standout
Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response
2018 StandoutNobel
Different frequencies and patterns of beta-catenin mutations in hepatocellular carcinomas induced by N-nitrosodiethylamine and a choline-deficient L-amino acid-defined diet in rats.
1999
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
2011 Standout
Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix.
2001 StandoutNobel
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Bladder Cancer
2020 Standout
Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density.
2001 StandoutNobel
Gene Expression in the Urinary Bladder
2004
Carbonic Anhydrase (CA IX) Expression, a Potential New Intrinsic Marker of Hypoxia: Correlations with Tumor Oxygen Measurements and Prognosis in Locally Advanced Carcinoma of the Cervix 1
2001 StandoutNobel
The sva package for removing batch effects and other unwanted variation in high-throughput experiments
2012 Standout
Cernilton for benign prostatic hyperplasia
2011
Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma
2001 StandoutNobel
Assay of serum allantoin in humans by gas chromatography–mass spectrometry
2002
Immune responses to transgene and retroviral vector in patients treated with ex vivo–engineered T cells
2010
Tumor‐associated Carbonic Anhydrases and Their Clinical Significance
2006
CAR T cell immunotherapy for human cancer
2018 StandoutScience
THE ROLE AND IMPACT OF PATHOLOGY REVIEW ON STAGE AND GRADE ASSESSMENT OF STAGES TA AND T1 BLADDER TUMORS: A COMBINED ANALYSIS OF 5 EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER TRIALS
2000
Multiple Binding Modes of Inhibitors to Carbonic Anhydrases: How to Design Specific Drugs Targeting 15 Different Isoforms?
2012 Standout
Works of E Okajima being referenced
Internal image anti‐idiotype antibodies related to renal‐cell carcinoma‐associated antigen G250
1994
Disturbance of the Cell Cycle with Colchicine Enhances the Growth Advantage of Diethylnitrosamine‐initiated Hepatocytes in Rats
1996
Chemopreventive Efficacy of Piroxicam Administered Alone or in Combination with Lycopene and β‐Carotene on the Development of Rat Urinary Bladder Carcinoma after A N‐Butyl‐N‐(4‐hydroxybutyl)nitrosamine Treatment
1997
Infrequent Ki-ras and an absence of p53 mutations in hepatocellular carcinomas induced by a choline deficient l-amino acid defined diet in rats
1996
CURRENT METHODS OF ASSESSING AND TREATING CARCINOMA IN SITU OF THE BLADDER WITH OR WITHOUT INVOLVEMENT OF THE PROSTATIC URETHRA
1995
Effect of sex hormones on development of urinary bladder tumours in rats induced by N-butyl-N-(4-hydroxybutyl) nitrosamine
1975
[Plasma allantoin in patients undergoing maintenance hemodialysis].
1996
Bladder tumors. Treated natural history.
1986
[Clinical evaluation of Cernilton on benign prostatic hypertrophy--a multiple center double-blind study with Paraprost].
1990
[Prophylactic effect of etretinate on the recurrence of superficial bladder tumors--results of a randomized control study].
1986
[Bropirimine (U-54461S) late phase II clinical study for carcinoma in situ of the bladder. Japan Bropirimine Study Group].
1997